Merck’s exceptional revenue growth in 2021 and the first half of 2022 came thanks to three big brands, one of which is not even approved by...
For all its forays elsewhere, diabetes remains the bedrock of Lilly’s business – and, if the Mounjaro launch goes as hoped, will continue to be so...
It’s often stated – mostly without reference to data – that the environment for innovative launches is more The post Is the launch environment really...
Newly Obtained Emails Shed More Light On CDC's False Vaccine Safety Monitoring Statements Authored by Zachary Stieber via The Epoch Times...
The number one fact in play right now for investors is risk aversion. According to Bank of America strategists, professional money managers are currently...
Ampio Pharmaceuticals Inc (OTCMKTS: AMPE) has hit the OTC with a thud closing out its first day of trading on the exchange down another 62% and...
The US currently has only one antibiotic available to treat gonorrhea – and it’s becoming less effective.
In this article, Ben Hargreaves takes a look at the renewed effort to tackle deaths from cancer in The post How data is crucial to the...
The International Vaccine Institute (IVI), an international organization with a mission to discover, develop, and deliver safe, effective, and affordable...
New York, NY (September 29, 2022) – The Icahn School of Medicine at Mount Sinai will award its inaugural 2022 Maria I. New International Prize for...
Graphite Bio is pioneering a precision gene editing approach that has the potential to transform health by achieving one of medicine’s most elusive goals:...
Martin Mendoza, PhD, director of health equity and health science policy for the All of Us Research Program The post The NIH on accelerating research using...
In the Phase II VISIONARY-MS trial (NCT03536559), which evaluated CNM-Au8 in participants with stable relapsing remitting multiple sclerosis (RRMS), CNM-Au8...
In the early days of the Covid-19 pandemic, when many trials were grounded, Jason Luke and his fellow clinical researchers at the University of Pittsburgh...
Neutrophils, the most abundant type of white blood cell, are the body’s first line of defense against infection. Foreign pathogens can stress the body...
Right around the beginning of the year, we got a close-up look at what happens after a boom ripples through biotech. The crash of life sciences...
Understanding how injury and disease, including COVID-19, can impair lung function can help researchers and clinicians better help patients who are experiencing...
Alexandre Le Vert, CEO and co-founder of Osivax, discusses the company’s breakthrough vaccine technology, oligoDOM, and how it’s The post Reconfiguring...
Jasmin A. Tiro, PhD, MPH, has joined the University of Chicago Medicine Comprehensive Cancer Center as the new Associate Director of Cancer Prevention...
This guidance replaces previous conditional recommendations for the use of these drugs and is based on emerging evidence that they’re not likely to work...
Alphabet subsidiary and precision health company Verily recently announced a breakthrough in its AI drug discovery GPCR research The post The future of...
By Joshua Brumm, CEO of Dyne Therapeutics, as part of the From The Trenches feature of LifeSciVC By all accounts, 2022 did not start according to...
In Alec Baldwin’s famous monologue from “Coffee’s For Closers”, he says – “The… The post Buzz on the Bullboards: The brighter side of a...
Anthony Fauci: From AIDS To COVID-19, A Pharma Love Story Opinion authored by Lorenzo Puertas via The Epoch Times (emphasis ours), After...
With countless media stories regarding COVID-19 published over a period of several years, it was obvious that people The post Rethinking trial engagement...
Geovax Labs Inc (NASDAQ: GOVX) is a highly volatile stock that spent most of its history on the OTC where we reported on it many times...
It’s all change at Alphabet’s life sciences business Verily, with a $1 billion funding round and a shake-up The post Verily raises $1bn to push ahead...
Now that most people in North America and Europe are vaccinated and the COVID-19 pandemic is diminishing, Moderna is looking for its second act.
PLYMOUTH MEETING, PA [September 12, 2022] — The National Comprehensive Cancer Network® (NCCN®) has published new NCCN Guidelines for Patients®: Marginal...
Here's what you need to know about trading penny stocks today The post Trending Penny Stocks You Need to Watch This Week appeared first on Penny...